Explore a comprehensive invited presentation from the 2022 Cancer Genomics Consortium Annual Meeting focusing on federated analysis for germline variant interpretation. Delve into the impact of genetics on cancer susceptibility and address the widespread issue of Variants of Uncertain Significance (VUS). Examine evidence-based VUS interpretation methods and explore privacy-preserving data sharing through federated analysis. Learn about federated allele frequency estimation and RNAseq analysis in pediatric cancer. Discover the four vital components for federated analysis, including container and workflow technologies, workflow security challenges, data specifications and standards, and data sharing policy compliance. Gain insights into the federated analysis of BioBank Japan data and understand how these approaches can advance cancer genomics and personalized medicine.